Selvita S.A. (WSE: SLV) - one of the largest preclinical contract research organizations in Europe, has signed a grant agreement with the National Centre for Research and Development for the development of a cell-based phenotypic platform based on high content imaging system integrated with artificial intelligence data analysis for multiple therapeutic areas, including neuroinflammatory and fibrosis drug discovery (HiScAI - High Content Screening Artificial Intelligence).

Selvita is an integrated service company providing multidisciplinary support in resolving the unique challenges of research within area of drug discovery, regulatory studies, as well as research and development. 

Selvita and Ardigen Will Receive Funding for the Development of an AI-based High-content Screening Platform

Selvita and Ardigen Will Receive Funding for the Development of an AI-based High-content Screening Platform

Company Info